A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Carotuximab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms AVANTE Study
- Sponsors Santen Pharmaceutical
- 06 Jul 2017 Status changed from planning to recruiting.
- 10 May 2017 According to a TRACON Pharmaceuticals media release, dosing will start in the second half of 2017.
- 03 Mar 2017 New trial record